Sustainability & Climate

Claire Elyse Brosseau launches an emergency legal bid to access assisted dying for mental illness, challenging Canada's repeated legislative delays.

Bill Ackman's ambitious Pershing Square USA fund saw a rocky NYSE launch, even as it drew high-profile global investors like Mexico's Jack Landsmanas.

New FDA-registered system from Clarapath offers labs a flexible, lower-cost entry into automation, targeting a critical bottleneck in pathology workflows.

Certor's VICIS and Schutt helmets top NFL/NFLPA safety tests, but as the tech moves to youth fields, experts caution that no helmet can truly stop a concussion.

Investors eye Star Bulk's Q1 results on May 20 as a bellwether for the shipping sector, with strong market signals and fleet changes in focus.

With two new acquisitions, Arete Health expands to 16 clinics, leveraging a unique partnership model to fuel its rapid consolidation in outpatient therapy.

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

A new precision timing chip from SiTime promises to unlock massive GPU potential in AI data centers, tackling a costly inefficiency holding back AI.

A new intraoperative MRI gives surgeons real-time vision, promising more precise and safer glioma removal as it moves toward the competitive U.S. market.

Amid market shifts and regulatory hurdles, a new webinar series from Phillips Lytle aims to provide developers with expert insights to build with confidence.

A new company, born from 15 years of military collaboration, emerges to redefine air and space power with advanced, drop-in propellants for U.S. forces.

Coca-Cola Consolidated is investing $35M in its Indianapolis plant for a new glass bottling line, a strategic move tapping into premium market trends.

With a fresh $26M, Enzo Health's AI platform aims to tackle clinician burnout and operational chaos in the booming but strained post-acute care market.

The non-profit is lauded for its internal culture and aid efforts, but a closer look reveals the complex realities behind its prestigious awards.

A German biotech's novel in vivo CAR T platform uses DNA for durable tumor control, aiming to make advanced cancer therapy an off-the-shelf medicine.

A strategic acquisition brings a top impairment expert's training under a leading online platform, set to redefine workers' compensation professional development.

A devastating infant liver disorder meets a potential breakthrough. Satellite Bio's novel cell therapy just received a critical FDA nod, paving the way for trials.

After a feature on CBS News Sunday Morning, a NY nonprofit sees its unique horse-assisted therapy validated on a national stage, facing new opportunities.

With its Juveena hydrogel pending FDA approval, Rejoni brings in a commercialization expert to tackle the underserved market for intrauterine adhesions.

Facing steep losses, FG Nexus is exploring a merger with its CEO's other firm, a move into affordable housing that tests both strategy and shareholder trust.